Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2015 Aug 5;15(12):771–777. doi: 10.1016/j.clml.2015.07.634

Table 4.

Base-Case Cost-Effectiveness Results

Regimen Total Incremental ICER

Cost LYs Saved QALYs Gained Cost LYs Saved QALYs Gained Cost per LY Saved Cost per QALY Gained
ATRA + AraC + Additional Chemotherapy $96,940 8.57 6.71 N/A N/A N/A N/A N/A
ATRA + IDA $101,396 10.09 8.13 $4,457 1.52 1.43 $2,993 $3,122
ATO + ATRA $136,170 17.79 14.33 $34,773 7.71 6.19 $4,512 $5,614

Note: LY = life year; QALY = quality-adjusted life year; ICER = incremental cost-effectiveness ratio.